keyword
MENU ▼
Read by QxMD icon Read
search

musso giovanni

keyword
https://www.readbyqxmd.com/read/28398481/mertk-rs4374383-variant-predicts-incident-nonalcoholic-fatty-liver-disease-and-diabetes-role-of-mononuclear-cell-activation-and-adipokine-response-to-dietary-fat
#1
Giovanni Musso, Maurizio Cassader, Franco De Michieli, Elena Paschetta, Silvia Pinach, Francesca Saba, Daria Bongiovanni, Luciana Framarin, Mara Berrutti, Nicola Leone, Stefania Corvisieri, Renato Parente, Federica Molinaro, Antonio Sircana, Simona Bo, Roberto Gambino
No abstract text is available yet for this article.
May 1, 2017: Human Molecular Genetics
https://www.readbyqxmd.com/read/28334911/mertk-rs4374383-variant-predicts-incident-nonalcoholic-fatty-liver-disease-and-diabetes-role-of-mononuclear-cell-activation-and-adipokine-response-to-dietary-fat
#2
Giovanni Musso, Maurizio Cassader, Franco De Michieli, Elena Paschetta, Silvia Pinach, Francesca Saba, Daria Bongiovanni, Luciana Framarin, Mara Berrutti, Nicola Leone, Stefania Corvisieri, Renato Parente, Federica Molinaro, Antonio Sircana, Simona Bo, Roberto Gambino
The loss-of-function rs4374383 G > A variant in Myeloid-epithelial-reproductive Tyrosine Kinase (MERTK) gene has been linked to hepatic fibrosis in chronic liver diseases. MERTK is expressed by immune and non-immune cells involved in inflammation, metabolism and vascular homeostasis. We assessed the impact of MERTK rs4374383 G > A variant on nonalcoholic fatty liver disease (NAFLD) incidence and severity and on glucose and lipid metabolism. We followed-up 305 healthy nonobese nondiabetic, metabolic syndrome-free insulin sensitive participants in a population-based study, characterized for MERTK G > A polymorphism, adipokine profile and inflammatory markers...
May 1, 2017: Human Molecular Genetics
https://www.readbyqxmd.com/read/28242789/tm6sf2-rs58542926-variant-affects-postprandial-lipoprotein-metabolism-and-glucose-homeostasis-in-nafld
#3
Giovanni Musso, Ugo Cipolla, Maurizio Cassader, Silvia Pinach, Francesca Saba, Franco De Michieli, Elena Paschetta, Daria Bongiovanni, Luciana Framarin, Nicola Leone, Mara Berrutti, Floriano Rosina, Stefania Corvisieri, Federica Molinaro, Antonio Sircana, Roberto Gambino
Mechanisms underlying the opposite effects of transmembrane 6 superfamily member 2 (TM6SF2) rs58542926 C>T polymorphism on liver injury and cardiometabolic risk in nonalcoholic fatty liver disease (NAFLD) are unclear. We assessed the impact of this polymorphism on postprandial lipoprotein metabolism, glucose homeostasis, and nutrient oxidation in NAFLD. Sixty nonobese nondiabetic normolipidemic biopsy-proven NAFLD patients and 60 matched controls genotyped for TM6SF2 C>T polymorphism underwent: indirect calorimetry; an oral fat tolerance test with measurement of plasma lipoprotein subfractions, adipokines, and incretin glucose-dependent insulinotropic polypeptide (GIP); and an oral glucose tolerance test with minimal model analysis of glucose homeostasis...
June 2017: Journal of Lipid Research
https://www.readbyqxmd.com/read/28241279/thiazolidinediones-and-advanced-liver-fibrosis-in-nonalcoholic-steatohepatitis-a-meta-analysis
#4
Giovanni Musso, Maurizio Cassader, Elena Paschetta, Roberto Gambino
Importance: Nonalcoholic steatohepatitis (NASH) is projected to be the leading cause of liver transplantation by 2020. Advanced fibrosis (stage F3-F4) on liver biopsy independently predicts all-cause and liver-related mortality in NASH. There are no known efficacious treatments for advanced fibrosis related to NASH. Thiazolidinedione therapy has been extensively evaluated in NASH, and new randomized clinical trials (RCTs) of its efficacy have been completed. Objective: To synthesize the evidence about the association of thiazolidinedione therapy with advanced liver fibrosis in NASH...
May 1, 2017: JAMA Internal Medicine
https://www.readbyqxmd.com/read/27880988/pioglitazone-for-advanced-fibrosis-in-nonalcoholic-steatohepatitis-new-evidence-new-challenges
#5
Giovanni Musso, Maurizio Cassader, Elena Paschetta, Roberto Gambino
No abstract text is available yet for this article.
November 23, 2016: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/27770583/a-population-based-study-of-chronic-myeloid-leukemia-patients-treated-with-imatinib-in-first-line
#6
Fausto Castagnetti, Francesco Di Raimondo, Antonio De Vivo, Antonio Spitaleri, Gabriele Gugliotta, Francesco Fabbiano, Isabella Capodanno, Donato Mannina, Marzia Salvucci, Agostino Antolino, Roberto Marasca, Maurizio Musso, Monica Crugnola, Stefana Impera, Elena Trabacchi, Caterina Musolino, Francesco Cavazzini, Giuseppe Mineo, Patrizia Tosi, Carmela Tomaselli, Michele Rizzo, Sergio Siragusa, Miriam Fogli, Riccardo Ragionieri, Alessandro Zironi, Simona Soverini, Giovanni Martinelli, Michele Cavo, Paolo Vigneri, Fabio Stagno, Gianantonio Rosti, Michele Baccarani
Chronic myeloid leukemia (CML) treatment is based on company-sponsored and academic trials testing different tyrosine kinase inhibitors (TKIs) as first-line therapy. These studies included patients selected according to many inclusion-exclusion criteria, particularly age and comorbidities, with specific treatment obligations. In daily clinical practice (real-life), inclusion-exclusion criteria do not exist, and the treatment outcome does not only depend on the choice of first-line TKI but also on second- and third-line TKIs...
January 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/27660122/fatty-liver-and-chronic-kidney-disease-novel-mechanistic-insights-and-therapeutic-opportunities
#7
REVIEW
Giovanni Musso, Maurizio Cassader, Solomon Cohney, Franco De Michieli, Silvia Pinach, Francesca Saba, Roberto Gambino
Chronic kidney disease (CKD) is a risk factor for end-stage renal disease (ESRD) and cardiovascular disease (CVD). ESRD or CVD develop in a substantial proportion of patients with CKD receiving standard-of-care therapy, and mortality in CKD remains unchanged. These data suggest that key pathogenetic mechanisms underlying CKD progression go unaffected by current treatments. Growing evidence suggests that nonalcoholic fatty liver disease (NAFLD) and CKD share common pathogenetic mechanisms and potential therapeutic targets...
October 2016: Diabetes Care
https://www.readbyqxmd.com/read/27521506/new-pharmacologic-agents-that-target-inflammation-and-fibrosis-in-nonalcoholic-steatohepatitis-related-kidney-disease
#8
Giovanni Musso, Franco De Michieli, Daria Bongiovanni, Renato Parente, Luciana Framarin, Nicola Leone, Mara Berrutti, Roberto Gambino, Maurizio Cassader, Solomon Cohney, Elena Paschetta
Epidemiologic data show an association between the prevalence and severity of nonalcoholic fatty liver disease and the incidence and stage of chronic kidney disease (CKD); furthermore, nonalcoholic steatohepatitis (NASH)-related cirrhosis has a higher risk of renal failure, a greater necessity for simultaneous liver-kidney transplantation, and a poorer renal outcome than cirrhosis of other etiologies even after simultaneous liver-kidney transplantation. These data suggest that NASH and CKD share common proinflammatory and profibrotic mechanisms of progression, which are targeted incompletely by current treatments...
August 10, 2016: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/27510649/erratum-to-donor-age-and-long-term-culture-do-not-negatively-influence-the-stem-potential-of-limbal-fibroblast-like-stem-cells
#9
Laura Tomasello, Rosa Musso, Giovanni Cillino, Maria Pitrone, Giuseppe Pizzolanti, Antonina Coppola, Walter Arancio, Gianluca Di Cara, Ida Pucci-Minafra, Salvatore Cillino, Carla Giordano
No abstract text is available yet for this article.
August 10, 2016: Stem Cell Research & Therapy
https://www.readbyqxmd.com/read/27296060/donor-age-and-long-term-culture-do-not-negatively-influence-the-stem-potential-of-limbal-fibroblast-like-stem-cells
#10
Laura Tomasello, Rosa Musso, Giovanni Cillino, Maria Pitrone, Giuseppe Pizzolanti, Antonina Coppola, Walter Arancio, Gianluca Di Cara, Ida Pucci-Minafra, Salvatore Cillino, Carla Giordano
BACKGROUND: In regenerative medicine the maintenance of stem cell properties is of crucial importance. Ageing is considered a cause of reduced stemness capability. The limbus is a stem niche of easy access and harbors two stem cell populations: epithelial stem cells and fibroblast-like stem cells. Our aim was to investigate whether donor age and/or long-term culture have any influence on stem cell marker expression and the profiles in the fibroblast-like stem cell population. METHODS: Fibroblast-like stem cells were isolated and digested from 25 limbus samples of normal human corneo-scleral rings and long-term cultures were obtained...
June 13, 2016: Stem Cell Research & Therapy
https://www.readbyqxmd.com/read/27127905/combination-of-bendamustine-and-rituximab-as-front-line-therapy-for-patients-with-chronic-lymphocytic-leukaemia-multicenter-retrospective-clinical-practice-experience-with-279-cases-outside-of-controlled-clinical-trials
#11
Massimo Gentile, Katja Zirlik, Stefania Ciolli, Francesca R Mauro, Nicola Di Renzo, Lucia Mastrullo, Francesco Angrilli, Stefano Molica, Giovanni Tripepi, Annamaria Giordano, Francesco Di Raimondo, Carmine Selleri, Marta Coscia, Maurizio Musso, Lorella Orsucci, Donato Mannina, Angela Rago, Angela Giannotta, Felicetto Ferrara, Yair Herishanu, Lev Shvidel, Tamar Tadmor, Ilaria Scortechini, Fiorella Ilariucci, Roberta Murru, Attilio Guarini, Gerardo Musuraca, Giuseppe Mineo, Iolanda Vincelli, Annalisa Arcari, Giuseppe Tarantini, Giuseppe Caparrotti, Annalisa Chiarenza, Luciano Levato, Maria Rosaria Villa, Maria Rosaria De Paolis, Pier Luigi Zinzani, Aaron Polliack, Fortunato Morabito
Recently, encouraging results in terms of safety and efficacy have been obtained using bendamustine-rituximab (BR) in untreated chronic lymphocytic leukaemia (CLL) patients enrolled in a phase II study. Here, we report a retrospective international multicenter study of CLL patients treated with BR as front-line therapy. The cohort included 279 patients with progressive CLL from 33 centers (29 Italian, 3 Israeli and 1 German) who received at least 1 cycle of BR as first-line treatment during the 2008-2014 period...
June 2016: European Journal of Cancer
https://www.readbyqxmd.com/read/26794269/non-alcoholic-steatohepatitis-emerging-molecular-targets-and-therapeutic-strategies
#12
REVIEW
Giovanni Musso, Maurizio Cassader, Roberto Gambino
Non-alcoholic fatty liver disease - the most common chronic liver disease - encompasses a histological spectrum ranging from simple steatosis to non-alcoholic steatohepatitis (NASH). Over the next decade, NASH is projected to be the most common indication for liver transplantation. The absence of an effective pharmacological therapy for NASH is a major incentive for research into novel therapeutic approaches for this condition. The current focus areas for research include the modulation of nuclear transcription factors; agents that target lipotoxicity and oxidative stress; and the modulation of cellular energy homeostasis, metabolism and the inflammatory response...
April 2016: Nature Reviews. Drug Discovery
https://www.readbyqxmd.com/read/26573228/lps-induced-tnf-%C3%AE-factor-mediates-pro-inflammatory-and-pro-fibrogenic-pattern-in-non-alcoholic-fatty-liver-disease
#13
Sara Ceccarelli, Nadia Panera, Marco Mina, Daniela Gnani, Cristiano De Stefanis, Annalisa Crudele, Chiara Rychlicki, Stefania Petrini, Giovannella Bruscalupi, Laura Agostinelli, Laura Stronati, Salvatore Cucchiara, Giovanni Musso, Cesare Furlanello, Gianluca Svegliati-Baroni, Valerio Nobili, Anna Alisi
Lipopolysaccharide (LPS) is currently considered one of the major players in non-alcoholic fatty liver disease (NAFLD) pathogenesis and progression. Here, we aim to investigate the possible role of LPS-induced TNF-α factor (LITAF) in inducing a pro-inflammatory and pro-fibrogenic phenotype of non-alcoholic steatohepatitis (NASH).We found that children with NAFLD displayed, in different liver-resident cells, an increased expression of LITAF which correlated with histological traits of hepatic inflammation and fibrosis...
December 8, 2015: Oncotarget
https://www.readbyqxmd.com/read/26463349/omega-3-fatty-acids-mechanisms-of-benefit-and-therapeutic-effects-in-pediatric-and-adult-nafld
#14
REVIEW
Valerio Nobili, Anna Alisi, Giovanni Musso, Eleonora Scorletti, Philip C Calder, Christopher D Byrne
Non-alcoholic fatty liver disease (NAFLD) is currently considered the most common liver disease in industrialized countries, and it is estimated that it will become the most frequent indication for liver transplantation in the next decade. NAFLD may be associated with moderate (i.e. steatosis) to severe (i.e. steatohepatitis and fibrosis) liver damage and affects all age groups. Furthermore, subjects with NAFLD may be at a greater risk of other obesity-related complications later in life, and people with obesity and obesity-related complications (e...
2016: Critical Reviews in Clinical Laboratory Sciences
https://www.readbyqxmd.com/read/26460265/klotho-a-new-marker-for-osteoporosis-and-muscle-strength-in-%C3%AE-thalassemia-major
#15
Alessandro Baldan, Andrea Giusti, Cristina Bosi, Cristina Malaventura, Marco Musso, Gian Luca Forni, Stefano Volpato, Giovanni Zuliani, Caterina Borgna-Pignatti
Aim of this study was to compare plasma levels of the secreted protein Klotho in β-thalassemia major patients and in healthy controls. Also, we examined the existence of correlations between the protein level and osteoporosis, poor muscle strength and fractures. A total of 106 patients with β-thalassemia major and 95 healthy blood donors were enrolled. Klotho level in plasma was measured by mean of an ELISA test and the hand-grip strength using a dynamometer. Intact parathyroid hormone (PTH), 25-hydroxy vitamin D (Vitamin D), serum calcium (Ca), phosphate (P), total alkaline phosphatase (ALP), ferritin, creatinine were measured by standard clinical techniques...
December 2015: Blood Cells, Molecules & Diseases
https://www.readbyqxmd.com/read/26432021/emerging-liver-kidney-interactions-in-nonalcoholic-fatty-liver-disease
#16
REVIEW
Giovanni Musso, Maurizio Cassader, Solomon Cohney, Silvia Pinach, Francesca Saba, Roberto Gambino
Mounting evidence connects non-alcoholic fatty liver disease (NAFLD) to chronic kidney disease (CKD). We review emerging mechanistic links between NAFLD and CKD, including altered activation of angiotensin converting enzyme (ACE)-2, nutrient/energy sensors sirtuin-1 and AMP-activated kinase, as well as impaired antioxidant defense mediated by nuclear factor erythroid 2-related factor-2 (Nrf2). Dietary fructose excess may also contribute to NAFLD and CKD. NAFLD affects renal injury through lipoprotein dysmetabolism and altered secretion of the hepatokines fibroblast growth factor-21, fetuin-A, insulin-like growth factor-1, and syndecan-1...
October 2015: Trends in Molecular Medicine
https://www.readbyqxmd.com/read/26069285/altered-gut-liver-axis-and-hepatic-adiponectin-expression-in-osas-novel-mediators-of-liver-injury-in-paediatric-non-alcoholic-fatty-liver
#17
Valerio Nobili, Anna Alisi, Renato Cutrera, Guido Carpino, Cristiano De Stefanis, Valentina D'Oria, Rita De Vito, Salvatore Cucchiara, Eugenio Gaudio, Giovanni Musso
BACKGROUND: Mechanism(s) connecting obstructive sleep apnoea syndrome (OSAS) to liver injury in paediatric non-alcoholic fatty liver disease (NAFLD) are unknown. We hypothesised alterations in gut-liver axis and in the pool and phenotype of hepatic progenitor cells (HPCs) may be involved in OSAS-associated liver injury in NAFLD. METHODS: Eighty biopsy-proven NAFLD children (age, mean±SD, 11.4±2.0 years, 56% males, body mass index z-score 1.95±0.57) underwent a clinical-biochemical assessment, with measurement of insulin sensitivity, plasma cytokines, lipopolysaccharide (LPS), an intestinal permeability test and a standard polysomnography...
August 2015: Thorax
https://www.readbyqxmd.com/read/25873773/osas-related-inflammatory-mechanisms-of-liver-injury-in-nonalcoholic-fatty-liver-disease
#18
REVIEW
Elena Paschetta, Paola Belci, Anna Alisi, Daniela Liccardo, Renato Cutrera, Giovanni Musso, Valerio Nobili
Obstructive sleep apnoea syndrome (OSAS) is a common sleep disorder, affecting over 4% of the general population, and is associated with metabolic syndrome and cardiovascular disease, independent of obesity and traditional risk factors. OSAS has been recently connected to nonalcoholic fatty liver disease (NAFLD), the most common chronic liver disease in the world, which can be found in 30% of the general adult population. Several studies suggest that the chronic intermittent hypoxia (CIH) of OSAS patients may per se trigger liver injury, inflammation, and fibrogenesis, promoting NAFLD development and the progression from steatosis to steatohepatitis, cirrhosis, and hepatocellular carcinoma...
2015: Mediators of Inflammation
https://www.readbyqxmd.com/read/25753820/obeticholic-acid-and-resveratrol-in-nonalcoholic-fatty-liver-disease-all-that-is-gold-does-not-glitter-not-all-those-who-wander-are-lost
#19
Giovanni Musso
No abstract text is available yet for this article.
June 2015: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/25646328/isoleucine-to-methionine-substitution-at-residue-148-variant-of-pnpla3-gene-and-metabolic-outcomes-in-gestational-diabetes
#20
RANDOMIZED CONTROLLED TRIAL
Simona Bo, Roberto Gambino, Guido Menato, Stefania Canil, Valentina Ponzo, Silvia Pinach, Marilena Durazzo, Ezio Ghigo, Maurizio Cassader, Giovanni Musso
BACKGROUND: A single nucleotide polymorphism (SNP) of the patatin-like phospholipase-3 (PNPLA3)/adiponutrin gene (rs738409 C>G) is strongly associated with nonalcoholic fatty liver disease; to our knowledge, no data are available on the impact of this PNPLA3 SNP on liver and metabolic outcomes during pregnancy in patients with gestational diabetes (GD). OBJECTIVE: We evaluated the impact of the PNPLA3 rs738409 SNP on liver enzymes, metabolic indexes, and maternal and neonatal outcomes in 200 GD patients enrolled in a lifestyle intervention...
February 2015: American Journal of Clinical Nutrition
keyword
keyword
118574
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"